logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5632.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5632.produseast1
Showing 1 - 3 of 3 Items
Showing 1 - 3 of 3 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Short Report

Continuing effectiveness of serogroup a meningococcal conjugate vaccine, Chad, 2013

Gamougam K, Daugla DM, Toralta J, Ngadoua C, Fermon F,  et al.
2015-01-01 • Emerging Infectious Diseases
2015-01-01 • Emerging Infectious Diseases
In 2011, vaccination with a serogroup A meningococcal polysaccharide conjugate vaccine was implemented in 3 of 23 regions in Chad. Cases of meningitis declined dramatically in vaccinated...
Journal Article
|
Short Report

Four years of case-based surveillance of meningitis following the introduction of MenAfriVac in Moissala, Chad: lessons learned

Page AL, Coldiron ME, Gamougam K, Acyl MA, Tamadji M,  et al.
2017-12-15 • Tropical Medicine and International Health
2017-12-15 • Tropical Medicine and International Health
Journal Article
|
Research

Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial

Daugla DM, Gami JP, Gamougam K, Naibei N, Mbainadji L,  et al.
2014-01-04 • Lancet
2014-01-04 • Lancet
A serogroup A meningococcal polysaccharide-tetanus toxoid conjugate vaccine (PsA-TT, MenAfriVac) was licensed in India in 2009, and pre-qualified by WHO in 2010, on the basis of its safe...